Purpose: The aim of this review is to provide an overview of novel clinical PET tracers in the pipeline for melanoma. Secondarily, to provide a head-to-head comparison with the current clinical standard used in clinical practice, [F]FDG, if available.
Recent Findings: [F]FDG PET/CT has become important in the clinical setting for melanoma as it serves many purposes, but lacks other important qualities due its nonspecific nature. There is an increased clinical need for specific tracers. Many new PET tracers, such as melanin-targeted and antibody-based probes, have been studied in melanoma with the intention of achieving high sensitivity detection of metastases and small lesions. There are four main groups of PET tracers in de pipeline for melanoma: melanin-, FAP-, PD-1/PD-L1- and CD8+ T cell-tracers. Melanin-targeted tracers and FAP inhibitors revealed potential for diagnostic application, whilst PD-1/PD-L1 and CD8+ T cell tracers demonstrated potential for response assessment and prediction. In conclusion, research has revealed promising results from current (ongoing) studies; however, more melanoma patients need to be included to further assess the value of these tracers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11912-025-01659-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spatial Distribution of Brain PET Tracers by MALDI Imaging.
J Am Soc Mass Spectrom
March 2025
The Maastricht MultiModal Molecular Imaging Institute (M4i), Division of Imaging Mass Spectrometry, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands.
Evaluating tissue distribution of Positron Emission Tomography (PET) tracers during their development conventionally involves autoradiography techniques, where radioactive compounds are used for visualization and quantification in tissues during preclinical development stages. Mass Spectrometry Imaging (MSI) offers a potential alternative, providing spatial information without the need for radioactivity with a similar spatial resolution. This study aimed to optimize a MSI sample preparation protocol for assessing PET tracer candidates with a focus on two compounds: UCB-J and UCB2400.
View Article and Find Full Text PDFNovel Clinical PET Tracers in the Pipeline for Melanoma.
Curr Oncol Rep
March 2025
Department of Nuclear Medicine, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
Purpose: The aim of this review is to provide an overview of novel clinical PET tracers in the pipeline for melanoma. Secondarily, to provide a head-to-head comparison with the current clinical standard used in clinical practice, [F]FDG, if available.
Recent Findings: [F]FDG PET/CT has become important in the clinical setting for melanoma as it serves many purposes, but lacks other important qualities due its nonspecific nature.
Emerging PET radiotracers for vascular imaging.
Rheumatology (Oxford)
March 2025
Section of Cardiorespiratory Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.
Imaging plays an important role in the clinical management of patients with large-vessel vasculitis (LVV), both to confirm the diagnosis at the time of initial presentation and to identify disease relapses in individuals with established disease. The big advantage of PET imaging over other non-invasive imaging modalities is the ability to employ targeted radionuclide probes to localize and track cellular pathways, providing in vivo assessments of disease activity. While 18F-fluorodeoxyglucose (FDG) has good diagnostic accuracy for LVV, this tracer is taken up by all glucose metabolizing cells in the vessel wall and so non-specific arterial uptake that is often unrelated to inflammatory disease activity can occur in patients despite a good clinical response to treatment.
View Article and Find Full Text PDFImpact of deep learning denoising on kinetic modelling for low-dose dynamic PET: application to single- and dual-tracer imaging protocols.
Eur J Nucl Med Mol Imaging
March 2025
Physics and Instrumentation, Department of Radiology, University of Pennsylvania, Philadelphia, PA, US.
Purpose: Long-axial field-of-view PET scanners capture multi-organ tracer distribution with high sensitivity, enabling lower dose dynamic protocols and dual-tracer imaging for comprehensive disease characterization. However, reducing dose may compromise data quality and time-activity curve (TAC) fitting, leading to higher bias in kinetic parameters. Parametric imaging poses further challenges due to noise amplification in voxel-based modelling.
View Article and Find Full Text PDFBinding Sites of a PET Ligand in Tau Fibrils with the Alzheimer's Disease Fold from F and C Solid-State NMR.
Biochemistry
March 2025
Department of Chemistry, Massachusetts Institute of Technology, 170 Albany Street, Cambridge, Massachusetts 02139, United States.
Aggregation of the tau protein into cross-β amyloid fibrils is a hallmark of Alzheimer's disease (AD) and many other neurodegenerative disorders. Developing small molecules that bind these tau fibrils is important for the diagnosis and treatment of tauopathies. Here, we report the binding sites of a positron emission tomography (PET) ligand, PI-2620, to a recombinant tau construct that adopts the C-shaped AD fold.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!